Monte Rosa Therapeutics Inc [GLUE] stock is trading at $5.95, down -8.18%. Until recently, the best way to gauge how the stock has performed was to look at its short-term value. The GLUE shares have gain 5.87% over the last week, with a monthly amount glided 5.68%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Monte Rosa Therapeutics Inc [NASDAQ: GLUE] stock has seen the most recent analyst activity on February 15, 2024, when Wedbush initiated its Outperform rating and assigned the stock a price target of $11. Previously, Wells Fargo upgraded its rating to Overweight on January 03, 2023, and kept the price target unchanged to $18. On October 13, 2022, UBS initiated with a Buy rating and assigned a price target of $22 on the stock. Jefferies started tracking the stock assigning a Buy rating and suggested a price target of $20 on August 15, 2022. Credit Suisse initiated its recommendation with a Neutral and recommended $19 as its price target on April 28, 2022. Wells Fargo started tracking with a Equal Weight rating for this stock on February 10, 2022, and assigned it a price target of $19. In a note dated October 14, 2021, SVB Leerink initiated an Mkt Perform rating and provided a target price of $20 on this stock.
Monte Rosa Therapeutics Inc [GLUE] stock has fluctuated between $2.44 and $8.84 over the past year. Monte Rosa Therapeutics Inc [NASDAQ: GLUE] shares were valued at $5.95 at the most recent close of the market.
Analyzing the GLUE fundamentals
Gross Profit Margin for this corporation currently stands at 0.47% with Operating Profit Margin at -9.61%, Pretax Profit Margin comes in at -8.95%, and Net Profit Margin reading is -8.99%. To continue investigating profitability, this company’s Return on Assets is posted at -0.38, Equity is -0.7 and Total Capital is -0.46. Upon thorough examination of the company’s fundamental financial framework, it becomes apparent that the debt-to-equity ratio stands at 0.2.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 5.71 points at the first support level, and at 5.47 for the second support level. However, for the 1st resistance point, the stock is sitting at 6.41, and for the 2nd resistance point, it is at 6.88.
Ratios To Look Out For
For context, Monte Rosa Therapeutics Inc’s Current Ratio is 6.56. As well, the Quick Ratio is 6.56, while the Cash Ratio is 2.57. Considering the valuation of this stock, the price to sales ratio is 63.39, the price to book ratio is 1.62.
Transactions by insiders
Recent insider trading involved Versant Venture Capital VI, L., 10% Owner, that happened on Sep 11 ’24 when 0.54 million shares were sold. 10% Owner, Versant Venture Capital VI, L. completed a deal on Sep 12 ’24 to sell 16047.0 shares. Meanwhile, 10% Owner Versant Venture Capital VI, L. sold 9269.0 shares on Sep 13 ’24.
